Welcome to our dedicated page for Bicycle Therapeutics plc American Depositary Shares news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics plc American Depositary Shares stock.
Bicycle Therapeutics plc (symbol: BCYC) is a pioneering clinical-stage biotechnology company with a mission to transform the pharmaceutical industry through its innovative Bicycle® product platform. This revolutionary platform focuses on developing a new class of medicines known as Bicycles, which are synthetic short peptides constrained to form two loops. These loops stabilize their structural geometry, granting them superior targeting abilities and efficiency compared to existing drug conjugate modalities.
The core business of Bicycle Therapeutics centers around creating transformational new therapies to enhance treatment options in oncology and other serious diseases. The company’s leading product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) designed to maximize tumor penetration while minimizing adverse effects on healthy tissues. Bicycles combine the beneficial properties of multiple therapeutic entities in a single modality – showcasing the affinity and selective pharmacology typical of antibodies, the rapid distribution kinetics of small molecules, and the adjustable pharmacokinetic half-life of peptides.
Bicycle Therapeutics is committed to addressing high unmet medical needs, particularly in oncology. Their proprietary IP is grounded in the groundbreaking work of scientific founders, and the company has made significant strides with their unique approach. Recent achievements include successful clinical trials and strategic partnerships aimed at advancing their robust pipeline of product candidates.
This innovative approach ensures that Bicycles exhibit a favorable safety profile and improved tolerability, making them a promising alternative to traditional therapies. As the company continues to evolve, it remains dedicated to enhancing patient outcomes and pioneering new treatment paradigms in the biotech space.
Bicycle Therapeutics (NASDAQ: BCYC) announced updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer (mUC). The combination showed a 65% overall response rate among efficacy-evaluable patients, with 50% confirmed responses in 20 patients. The safety profile remained consistent with previous studies, with no patient withdrawals due to treatment-related adverse events.
The company outlined its 2025 strategic priorities, including expanding zelenectide pevedotin trials across multiple Nectin-4 associated cancers, with Phase 1/2 trials planned in breast cancer, lung cancer, and multiple tumors. Additional milestones include reporting Phase 2/3 Duravelo-2 dose selection data and advancing their radiopharmaceuticals pipeline.
As of September 2024, Bicycle reported $890.9 million in cash and cash equivalents, with an expected financial runway into second half of 2027.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, which will be followed by a Q&A breakout session at 5:35 p.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website at www.bicycletherapeutics.com. The company will also make a replay of the webcast available on their website after the event.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to 12 new employees. The awards, approved by the Compensation Committee of the company's Board of Directors on January 2, 2025, consist of non-qualified share options to purchase a total of 67,300 ordinary shares.
The options were granted under Bicycle's 2024 Inducement Plan with an exercise price of $14.00 per share, matching the company's closing price on December 31, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Inducement Plan terms and conditions.
Bicycle Therapeutics (NASDAQ: BCYC) announced significant data updates for its zelenectide pevedotin program. The drug showed a 60% overall response rate when combined with pembrolizumab in first-line metastatic urothelial cancer. In breast cancer patients with NECTIN4 gene amplification, the drug demonstrated a 62.5% response rate, while NSCLC patients with NECTIN4 gene amplification showed a 40% response rate.
The company plans to advance its development strategy focusing on NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer, and multi-tumor planned for 2025. Dose selection and topline data from the Phase 2/3 Duravelo-2 trial are expected in 2H 2025.
Bicycle Therapeutics (NASDAQ: BCYC) has expanded its Clinical Advisory Board with three distinguished oncology experts to support its clinical oncology programs development. The new members include: Howard A. 'Skip' Burris III, president and chief medical officer of Sarah Cannon Research Institute; Markus Eckstein, senior consultant pathologist at University Hospital Erlangen; and Niklas Klümper, senior consultant for Urology & Genitourinary Oncology at University Hospital Bonn.
Each expert brings specialized experience: Burris in first-in-human therapies and FDA-approved treatments, Eckstein in genitourinary pathology and systems immunology, and Klümper in precision oncology and drug conjugate development.
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to thirteen new employees on December 2, 2024. The awards consist of non-qualified share options to purchase 62,400 ordinary shares at an exercise price of $20.40 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months. These grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) announced upcoming presentations of data for zelenectide pevedotin at the 2024 San Antonio Breast Cancer Symposium. The company will present findings showing enhanced anti-tumor activity in triple-negative breast cancer patients with NECTIN4 gene amplification.
Additionally, Bicycle will announce topline data for zelenectide pevedotin plus pembrolizumab combination in first-line metastatic urothelial cancer patients, and monotherapy results in non-small cell lung cancer patients. The poster presentation, led by Dr. Niklas Klümper from University Hospital Bonn, is scheduled for December 12. A conference call to discuss these updates will be held on December 13.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company developing innovative therapeutics using its proprietary bicyclic peptide technology, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 19, 2024, at 10:30 a.m. GMT. Investors and interested parties can access a live webcast of the presentation through the company's website, with a replay available after the event.
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to twelve new employees on November 1, 2024. The awards consist of non-qualified share options to purchase 56,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $23.44 per share, based on the closing price on October 31, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.
Bicycle Therapeutics (NASDAQ: BCYC) reported Q3 2024 financial results and business updates. Key highlights include a 45% overall response rate for both zelenectide pevedotin and BT5528 in metastatic urothelial cancer trials. The company's cash position stands at $890.9 million as of September 30, 2024, with runway extending into 2H 2027. Q3 showed a net loss of $50.8 million, or $(0.74) per share. R&D expenses increased to $48.3 million, up from $39.9 million in Q3 2023, while G&A expenses rose to $18.3 million from $16.3 million year-over-year.
FAQ
What is the current stock price of Bicycle Therapeutics plc American Depositary Shares (BCYC)?
What is the market cap of Bicycle Therapeutics plc American Depositary Shares (BCYC)?
What is Bicycle Therapeutics plc?
What are Bicycles in the context of Bicycle Therapeutics?
What is the main focus of Bicycle Therapeutics' research and development?
What is BT1718?
What makes Bicycles different from traditional drug conjugates?
What recent achievements has Bicycle Therapeutics made?
How does Bicycle Therapeutics' technology improve patient outcomes?
What is the significance of Bicycle Therapeutics' proprietary IP?
Who are the founders of Bicycle Therapeutics?
What is the strategic goal of Bicycle Therapeutics?
